Project Experience (sampling not all inclusive) |
Project Description |
| Phase |
Indication |
N° Countries |
N° Patients |
Role |
Phase I/II
|
An international multi-center dose comparison study of intranodal honeybee venom vaccination. In addition, A follow-up study of subjects who have completed protocol to evaluate long-term safety and efficacy of vaccine. |
5
|
200
|
CRO |
Phase IV |
A Stratified, Randomized, Prospective, Un-blinded, Active-Control Trial of two therapies for the Treatment of Community Acquired Pneumonia and Versus Amoxicillin/clavulanate® for the Treatment of Acute Bacterial Exacerbation of Chronic Bronchitis |
|
|
Partner |
Phase IV |
A prospective Study of Neutropenic Complications |
|
|
Partner |
Phase IV |
Mulicenter Assessment of Transdermal therapy in overactive bladder |
|
|
Partner |
Phase IV |
Treatment of anemia in subjects with Chronic Renal Failure (CRF). To evaluate subject preference for the therapy administered once monthly, ie every 4 weeks (Q4W) or the alternate therapy administered once weekly (QW). To assess subject productivity and subject selection of the therapies in the parallel arm portion and at study conclusion. |
|
|
CRO |
Phase Ib/II |
Brand of S6F1 Antibody Pharmacokinetic
and Dose-Ranging Study in HIV Seropositive Patients. |
|
|
CRO |
Phase I |
Open-Label, Dose-Escalation Study,
Administered Orally as a Single Dose, in Healthy Volunteers of Desirable Weight and in
Obese Volunteers at Selected |
|
|
CRO |
Phase III |
The Talent E-LPS Endoluminal Stent Graft System is indicated for the endovascular treatment of Abdominal Aortic Aneurysms with or without Iliac Involvement. This is accomplished by the Endovascular Placement of a Stent-Graft to isolate the Aneurysm from blood flow. |
|
|
CRO |
Phase III |
An Investigation of a Endoluminal Stent-Graft System for the Treatment of Thoracic Aortic Aneurysms in Patients who are Candidates for Standard Surgical Intervention. |
|
|
CRO |
Phase II |
A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects with Severe Hyperinflation. |
|
|
CRO |
